2024 VC forecast: Clinical-stage CDMOs likely to have uptick in demand but specialization critical

Clinical-stage CDMOs should expect a rise in demand in 2024 as funding for early-stage biopharma stabilizes and biotechs may shed their in-house manufacturing to save cash, according to three VCs interviewed by Endpoints News.

“If you’re a biotech company and you don’t have to invest in your own manufacturing infrastructure,…
Click here to view original post